TROPICAL DISEASE FOUNDATION, INC.

Annual Report

2021-2022

Dear Friends, & Partners . . .

I was given the responsibility to lead TDF in July 2022. I am humbled by the trust and confidence bestowed upon me by the Board, and proud in what our team of outstanding employees has built over the last 38 years. I am even more excited about where we can go next. TDF is a significant player in TB research, and a leader in building a movement for its control and eventual eradication as a major disease of public health importance in the country. And we are just gearing up again for more initiatives that were slowed down by the challenges brought about by the recent covid pandemic.

HOPE FOR THE FUTURE: Our Foundation proved resilient at the time when many nonprofits failed to survive. The organization remained strong during the pandemic with the leadership of my predecessor, Dr. Roberta C. Romero. More nonprofits and mission-driven organizations here and around the globe will understand and embrace the power of teamwork to create impact partnerships to fuel their organizations. Using our well-positioned brand, excellent talent, and best practices to expand the reach and practice of high-impact initiatives across the country, TDF can lead the way towards that reality.

We have a very strong reputation in our communities. We have partners both local and international, other nonprofits, academic institutions, and government, which together with our corporate clients, and network of professional experts continue to work with us in common disease areas of interest. These are just some of the assets that have set us up to lead, expand, and sustain this movement.

OVER THE NEXT THREE YEARS, we will create more partnerships with other nonprofits and social change organizations directly by teaming up with them. We will expand our programs to "enable" other intermediaries and groups to offer high-impact and integrated projects and programs through research, service delivery, training, and sharing best practices. We will continue to "inspire" others to engage and team-up with us in projects and programs across the country. We are recommitting to focus on our primary beneficiaries and with other social change organizations to bring better health outcomes to patients.

Our existing programs and services are important building blocks to continue to have maximum impact in our communities, but we will begin to reach beyond our current programs and domains to address opportunities and demand across the country. New programs with the use of innovative tools, products, and technologies will be employed to access and deliver high-impact key results. This will be a major part of our strategy to expand our reach to significantly more beneficiaries.

We have already a solid name and legacy from our Founder, Dr. Thelma E. Tupasi, and we have an eagle's eye on continued healthy and strategic growth. As you read more about us, I hope you will imagine yourself as our future partner for change.

Julius A. Lecciones, MD, PhD, DPA
PRESIDENT AND CEO

About TDF

The Tropical Disease Foundation, Inc. is a private, non-stock, non-profit, nongovernment organization founded in 1984 by a group of physicians in the Research Institute for Tropical Medicine. The founding chairman was Dr. Jesus Azurin, then Secretary of Health. The TDF began a legacy of quality research, service and training in infectious diseases.

Our Vision and Mission

The Tropical Disease Foundation, Inc. believes in equitable, universal access to health for economic prosperity. Its programs and projects encourage participation in the national and local communities through its research, training, health care service provision and advocacies.

Our Thrusts

1. To conduct research, training and service in infectious diseases of public health importance
2. To enter into partnership with public and private agencies in the implementation of programs in the control of infectious diseases
3. To ensure technology transfer in developing human resources for health nationally and internationally through collaboration with national and international institutions
4. To serve as a national and international training center for infectious diseases

Researches

1. TRUNCATE -TB CLINICAL TRIAL

- *Protocol Title:* "Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis"
- *Sponsor:* University College London (UCL)/ National University Hospital (NUH) Singapore
- *Principal Investigators:* Thelma E Tupasi, MD†,
  Dr. Rholine Gem Martin Veto

Objectives:

- The primary aim is to test the hypothesis that the TRUNCATE-TB management strategy is non-inferior to the standard TB management strategy assessed by the proportion of patients with unsatisfactory outcome at 2 years after randomisation.
- The secondary aim is to assess the possible advantages of the TRUNCATE-TB management strategy compared to the standard management strategy from the patient perspective, the programme perspective and to assess cost-effectiveness.

Study Updates:

Ethics Committee Initial Approval: ..... 19 Jan 2017
Coordinator's meeting: ..... 09 Feb 2018
Site Initiation visit: ..... 12 Feb 2018
First subject enrolled: ..... 13 Apr 2018
End of recruitment: ..... 18 Mar 2020
Total patients screened: 66
Total patients randomized: 42
Close-out visit: ..... 17 Dec 2021

Principal Investigator and Study Coordinator attended the Study Results Meeting last 02 JUN 2022 in Singapore c/o Coordinating Center. All sites globally were represented, and preliminary results of the study were presented.

TRUNCATE-TB Coordinating Center Staff with Site Personnel during TRUNCATE-TB Results Meeting last June 2022.

2. Gates MRI TBV02-E01

- *Protocol Title:* Epidemiologic Study to assess the IGRA positivity in populations with a High TB burden.
- *Protocol Name:* Gates MRI TBV02 – E01
- *Sponsor:* The Bill & Melinda Gates Medical Research Institute
- *Investigators:* Rholine S Veto, MD (PI),
  Josella Mirandilla, MD (CoI)
- *Site Initiation:* 25 July 2022
- *Trial Duration:* 3 years
- *Objective:* To assess the proportion of IGRA positivity, by site, and to build capacity to conduct a pivotal Phase 3 TB vaccine efficacy study. The study is not designed to generalize findings regarding the prevalence of latent TB. No investigational product/intervention is administered. Participants are from the broad general population in selected areas from Makati, Pasay, and Manila.

3. Paternity Survey

- *Protocol Title:* A Survey Assessing Male Reproduction During or After Treatment Containing Pretomanid
- *Survey Protocol Name:* Paternity Survey
- *Sponsor:* Global TB Alliance
- *Principal Investigator:* Dr. Janice Caoili. MD
- *Initiation Date:* 07 June 2021
- *Study Duration:* 8 months
- *Description:* This survey will collect information regarding reproduction in male participants who have received treatment containing pretomanid as part of their participation in a TB Alliance clinical trial (STAND, Nix-TB, SimpliciTB or ZeNix). Participants will be asked to complete a questionnaire about partner births that occurred while receiving pretomanid, or after they completed pretomanid containing regimen.

4. SimpliciTB Clinical Trial

- *Protocol Title:* "An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants with Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)."

- *Protocol Name:* SimpliciTB
- *Study Protocol No.:* NC-008 (B-Pa-M-Z)
- *Sponsor:* Global Alliance for TB Drug Development
- *Principal Investigator:* Dr. Janice Caoili

Ethics Committee Initial Approval:	21 May 2018
Site Initiation Visit:	23 January 2019
First patient enrolled:	04 Mar 2019
Total patients enrolled to date:	18
Total patients randomized:	9
Site Close-out Visit:	22 July 2022

5. Inactivated COVID-19 Vaccine (Vero Cells)

A study to evaluate efficacy, safety and immunogenicity of SARS- CoV-2 Vaccine (Vero Cells), inactivated in healthy adults aged 18 years and older.

- *Sponsor:*
  Shenzhen Kangtai Biological Products Co., Ltd.
  Beijing Minhai Biological Technology Co., Ltd.
- *Site:* Tropical Disease Foundation, Inc - Makati
- *Principal Investigator:* Dr. Gelza Mae A. Zabat

Study Updates

Ethics Committee Initial Approval: .... 29 Jun 2021
Site Initiation Visit: ..... 03 Aug 2021
Start of enrollment: ..... 14 Aug 2021
End of enrollment: ..... 15 Oct 2021
Total enrolled: 1251
Trial Duration: ..... 18 months
Status: ..... For Close-Out

6. DelNS1-2019-nCoV-RBD-OPT1)

A Global, Multi-center, Randomized, Double-blind, Placebo controlled Phase III Clinical Trial to Evaluate the Protective Efficacy and Safety of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1) in Adults Aged 18 Years and Older.

- *Sponsor:* Shenzhen Kangtai Biological Products Co., Ltd.
  Beijing Minhai Biological Technology Co., Ltd.
- *Site:* Tropical Disease Foundation, Inc - Makati
- *Principal Investigator:* Dr. Gelza Mae A. Zabat

Study Updates

Ethics Committee Initial Approval: ..... 24 Sep 2021
Site Initiation Visit: ..... 14 Dec 2021
Start of enrollment: ..... 18 Dec 2021
End of enrollment: .....11 Feb 2022
Total enrolled: 1594
Trial Duration: ..... 18 months
Status: ..... Completed

7. ARCoV-005

A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine in Population Aged 18 Years and Older (ARCoV-005)

- *Sponsor:* Yuxi Walvax Biotechnology Co., Ltd., Walvax Biotechnology Co.,Ltd. & Suzhou Abogen Biosciences Co., Ltd.
- *Site:* Tropical Disease Foundation, Inc.
  Bautista, Pangasinan Local Government Unit
- *Principal Investigator:* Dr. Rod Castro

Study Updates

Ethics Committee Initial Approval: ..... 03 Aug 2021
Site Initiation Visit: ..... 30 Nov 2021
Start of enrollment: ..... 5 Dec 2021
End of enrollment: ..... 16 Feb 2022
Total enrolled: 821
Trial Duration: ..... Nov. 30, 2021 to Sep. 6, 2023
Status: ..... End of Study


WELCOME
PRIMICIAS BARANGAY PLAZA


PRIMICIAS


WELCOME
WALVAX SPONSORS

TDF Medical Research Unit (MRU) Researches

The TDF - Medical-Research Unit (MRU) founded last October 2019 is headed by one of the country's top clinical researcher, Dr. Maria Rosario Zeta Capeding. Dr. Rose is a pediatrician specializing in infectious disease. A memorial awardee of Dr. Jose P. Rizal in research and a Scientist II of the Department of Science and Technology, she has worked as lead investigator in various clinical trials.

8. Clinical Trials under Dr. Rose Capeding as Principal Investigator

A. VAC31518COV3009

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

- *Sponsor:* Janssen Vaccines & Prevention B.V.
- *Site:* San Francisco Multipurpose Bldg., San Pablo City, Laguna

Study Updates

Ethics Committee Initial Approval:.....28 December 2020
Site Initiation Visit: .....25 January 2021
Start of enrollment:..... 06 February 2021
End of enrollment: .....30 March 2021
Total enrolled: 308
Trial Duration: .....2 years
Study Status:..... Completed

San Pablo City Clinical Trial Team

B. GBP510_003

A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine adjuvanted with AS03 (GBP510) in Adults Aged 18 Years and Older

- *Sponsor:*
  International Vaccine institute/SK Bioscience Co. Ltd.
- *Site:*
  San Francisco Multipurpose Bldg., San Pablo City, Laguna

Study Updates

Ethics Committee Initial Approval:.....05 October 2021
Site Initiation Visit: ..... 02 December 2021
Start of enrollment:..... 06 December 2021
End of enrollment: .....29 December 2021
Total enrolled: 682
Trial Duration: .....13 months
Study Status:..... Completed

San Pablo City Clinical Trial Team (IVI)

c. JSVCT109

A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older

- *Sponsor:*
  WesVac Biopharma Co., Ltd.
- *Site:*
  Alaminos Clinical Trial Site, Alaminos, Laguna

Study Updates

Ethics Committee Initial Approval:..... 29 June 2021
Site Initiation Visit: ..... 12 July 2021
Start of enrollment:..... 22 July 2021
End of enrollment: .....08 December 2021
Total enrolled: 3054
Trial Duration: .....13 months
Study Status:..... Completed


Alaminos, Laguna Clinical Trial Team


MRU Clinical Trial Team

D. GC3107_P3

A Multi-national, Multi-center, Randomized, Double-Blind, Active Controlled, Phase III Study to Investigate the Efficacy and Safety of 'GC3107 (BCG Vaccine)'after Intradermal Administration in Healthy Infants

- *Sponsor:*
  Green Cross Corporation
- *Site:*
  TDF-MRU-Medical Plaza, Makati City

Study Updates

Ethics Committee Initial Approval:..... 07 May 2021
Site Initiation Visit: ..... 27 October 2021
Start of enrollment:..... 30 October 2021
End of enrollment: ..... 15 March 2022
Total enrolled: 150
Trial Duration: ..... 13 months
Study Status:..... Completed

E. YS-302

A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety, and Immunogenicity of a Booster Dose of PIKA-Adjuvanted Recombinant Protein SARS-CoV-2Spike (S) Subunit Vaccine in Adults ≥ 18 Years Old Who Received 2 or more doses of Inactivated Covid-19 Vaccine

- *Sponsor:*
  Yisheng Biopharma (Singapore) Pte. Ltd.
- *Site:*
  Presnedi Building. Muntinlupa City

Study Updates

Ethics Committee Initial Approval:..... 22 August 2022
Site Initiation Visit: .....19 September 2022
Start of enrollment:.....27 October 2022
End of enrollment: .....20 December 2022
Total enrolled: 1502
Trial Duration: .....13 months
Study Status..... Surveillance phase

Muntinlupa City Clinical Trial Team

A. CLO-SCB-2019-003 Study

A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/ Alum-Adjuvanted Recombinant SARS- CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2-mediated COVID-19 in Participants Aged 12 Years and Older.

Description: CLO-SCB-2019-003 is a double-blind, randomized, controlled, multi-country study of CpG 1018/Alumadjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) to assess the efficacy, immunogenicity, reactogenicity, and safety compared with control (placebo). The study will include adult subjects aged 18 years and older, and adolescents 12 to less than 18 years of age, enrolled at selected sites.

Sponsor: Clover Biopharmaceuticals AUS Pty Ltd

Site: Health Index Multispecialty Clinic
Barangay Mambog 1, Bacoor, Cavite 4102 Philippines

Study Updates
Site Initiation Visit: ..... 12 January 2021
Study Duration: ..... 13 months

Adult:
Screening: ..... 24 March 2021
Enrollment Started (First Subject): ..... 24 March 2021
Enrollment Finished (Last Subject): ..... 29 June 2021
Total No. of Subjects Screened: 1675
Total No. of Screen Failed: 92
Total No. of Subjects Enrolled 1583

Adolescent:
Date of Screening Started (Adolescent) ..... 05 Jan 2022
Date Enrollment Started (First Subject) ..... 05 Jan 2022
Date Enrollment Finished (Last Subject) ..... 14 Mar 2022
Total No. of Subjects Screened 202
Total No. of Screen Failed 12
Total No. of Subjects Enrolled 190

B. HH-Trans-001 Study

Impact of Vaccination using the Clover SCB-2019 COVID-19 vaccine on Household Transmission of SARS-CoV-2 Infection.

Description: Observational Study. The total incidence rate of SARS-CoV-2 infection, adjusted for the intraclass correlation within household, among household members not participating in the Clover SCB-2019 trial.

Sponsor: International Vaccine Institute (IVI)
Site: Health Index Multispecialty Clinic
Barangay Mambog 1, Bacoor, Cavite 4102 Philippines

Study Updates:
Site Initiation Visit: ..... 30 June 2021
Study Duration: 8 weeks after the second dose of SCB-2019; the actual duration will depend on the duration of the main trial.
Date of Initiation Visit: ..... 30 June 2021
Date of Screening Started: ..... 14 July 2021
Date Enrollment Started (First Subject): ..... 14 July 2021
Date Enrollment Finished (Last Subject) ..... 06 Oct 2021
Total No. of Subjects Screened 640
Total No. of Screen Failed 0
Total No. of Subjects Enrolled 640
Last Subject Visit (End of Study Visit) ..... 03 Feb 2022

C. 2021L001 Study

A multi-national, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety and immunogenicity of SARS- CoV-2 Vaccine (Vero Cells), Inactivated for the prevention of COVID-19 in healthy adults aged 18 years and older

Description:
Study Objective is to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in healthy adults aged 18 years and older.

Primary study objective:
To evaluate the efficacy of candidate vaccine in the prevention of symptomatic COVID-19 cases 14 days after full vaccination, in healthy adults aged 18 years and older.

Sponsor: Shenzhen Kangtai Biological Products Co., Ltd.
Beijing Minhai Biotechnology Co., Ltd.

Site: Health Index Multispecialty Clinic
Barangay Mambog 1, Bacoor, Cavite
4102 Philippines

Study Updates:

Site Initiation Visit: ..... 09 August 2021

Study Duration:
Participants will be followed for at least 12 months after full vaccination. Based on primary endpoint and anticipated enrollment period per country of 2~6 months, the study is anticipated to last for 15~19 months.

Date of Initiation Visit: ... 30 June 2021

Date of Screening Started:..... 16 Aug 2021

Date Enrollment Started (First Subject): ..... 19 August 2021

Date Enrollment Finished (Last Subject) ..... 30 October 2021

Total No. of Subjects Screened 2560

Total No. of Screen Failed 484

Total No. of Subjects Enrolled 2076

D. GBP510_003 Study

A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine adjuvanted with AS03 (GBP510) in Adults Aged 18 Years and Older.

Description: The purpose of this study is to assess the immunogenicity and safety of SK SARS-CoV-2 recombinant protein nanoparticle vaccine adjuvanted with AS03 (GBP510) in adults aged 18 years and older.

This is a Phase III, randomized, active-controlled, observer-blind, parallel-group, multi-center study to compare the immunogenicity and safety of SK SARS-CoV-2 recombinant protein nanoparticle vaccine adjuvanted with AS03 (GBP510) to ChAdOx1-S in adults aged 18 years and older.

Approximately 1,950 adults with no history of SARS-CoV-2 infection and COVID-19 vaccination confirmed by a SARS-CoV-2 rapid antibody kit at screening will be enrolled in Cohort 1 (Immunogenicity Cohort), and another 2,040 adults will be enrolled in Cohort 2 (Safety Cohort) regardless of their serostatus confirmed by a SARS-CoV-2 rapid antibody kit at screening. Approximately 20% of the participants will be elderly population aged 65 years and older.

Sponsor: SK Bioscience Co., Ltd.
International Vaccine Institute (IVI)

Site: Health Index Multispecialty Clinic
Barangay Mambog 1, Bacoor, Cavite 4102 Philippines

Study Updates:

Site Initiation Visit: ..... 01 December 2021

Study Duration:
Participants are expected to participate for up to a maximum of approximately 13 months. A 12- month study follow-up after the 2nd vaccination will be conducted.

Date of Screening Started: 06 December 2021

Date Enrollment Started (First Subject): .... 14 December 2021

Date Enrollment Finished (Last Subject): ..... 07 January 2022

Total No. of Subjects Screened	
Cohort 1 (Immunogenicity)	*= 140*
Cohort 2 (Safety)	*= 718*
Total Subjects	*= 858*

Total No. of Screen Failed	
Cohort 1 (Immunogenicity)	*= 10*
Cohort 2 (Safety)	*= 174*
Total Subjects	*= 184*

Total No. of Subjects Enrolled	
Cohort 1 (Immunogenicity)	*= 130*
Cohort 2 (Safety)	*= 544*
Total Subjects	*= 674*

E. KD414-03 Study

A Phase 3, Randomized, Double-Blind, Active-Controlled, Confirmatory Study to Compare the Immunogenicity, Efficacy, and Safety of KD-414 Vaccine and Vaxzevria Vaccine in Adults Aged 18 to 40 Years Old.

Description: The KD-414 vaccine is being developed to prevent COVID-19, the disease resulting from SARS-CoV-2 infection. The current study has been designed to primarily evaluate the immunogenicity of KD-414 to prevent COVID-19. The study will also evaluate the efficacy and safety of KD-414. A Phase 1/2 study is being conducted with KD-414. So far there have been no safety concerns for the addition of the third dose with 6-month interval.

This Phase 3 study is designed to be a randomized, stratified, double-blind, active-controlled study to compare the immunogenicity, efficacy, and safety of KD-414 SARS-CoV-2 vaccine and Vaxzevria ® vaccine in subjects aged 18 to 40 years old who have no known history of SARS-CoV-2 infection.

Sponsor:

Site: Health Index Multispecialty Clinic
Barangay Mambog 1, Bacoor, Cavite 4102 Philippines

Study Updates:

Initiation Visit: ..... 07 June 2022
Date of Screening Started: ..... 01 July 2022
Date Enrollment Started (First Subject): ..... 01 July 2022
Date Enrollment Finished (Last Subject): ..... 22 July 2022
Total No. of Subjects Screened: 333
Total No. of Screen Failed: 142
Total No. of Subjects Enrolled: 191


Services

1. TDF TB-DOTS Clinic



TDF offers a public-private mixed DOTS clinic for patients who have symptoms suggestive of TB or who are suspected to have tuberculosis by healthcare providers. DOTS is the most effective means of controlling the spread of tuberculosis and by involving the public and the private sector, case finding and engagement to treatment is intensified.

TDF TB-DOTS Clinic caters to patients who live or work within the catchment area whether they are walk-in patients or referrals by physicians of nearby hospitals such as Makati Medical Center, diagnostic clinics, schools, business establishments and offices.

TDF-DOTS Clinic envisions achievement of the millennium development goal by continuing to serve more clients in the years to come. Since the onset of the pandemic, the clinic has implemented community-based treatment, using technologic tools to perform remote monitoring of patients.

- *Sponsoring Organization:*

TB kits (drugs) and laboratory supplies are provided by National TB Program through the Makati City Health Department.

- *Accomplishments*:

Number of Presumptive TB cases Screened: . 192 (up 84% from 2021)
Number of Patients Enrolled: ..... 63 (up 231% from 2021)
Number of Patient Completed treatment:
Cured: 22
Treatment Completed: 28
Ongoing Treatment: 5

2. TDF-Satellite Treatment Center for DR-TB

The performance of the Satellite Treatment Center (STC) in the past year is as follows:

- Number of All Presumptive DR-TB Screened: ..... 171 (up 24% from 2021)
- Number of All Presumptive DR-TB Tested: 137
- Number of All Confirmed Rifampicin Resistant TB: 15
- Number of cases registered: 27

o Bacteriologically-confirmed RR/MDR-TB: 12
o Clinically-diagnosed MDR-TB: 10
o Other Drug-resistant TB case: 5

The STC continues to provide DRTB management services, primarily catering to referrals from Makati Medical Center, and Barangay Pio Del Pilar. As of 31 July 2022, the STC census is at 25 patients, including patients supervised by Community Treatment Partners (CTPs). The STC currently has 1 PBSP-hired nurse on board. Outside of scheduled follow-up visits, patients are monitored regularly through phone calls and/or internet messaging platforms in between monthly clinic visits.

3. Rapid TB Diagnostic Laboratory (RTDL) of the PMDT program

TDF laboratory is also a Rapid TB Diagnostic Laboratory (RTDL) of the Programmatic Management of Drug-Resistant TB patients. As an RTDL, TDF performs GeneXpert MTB/RIF assay for the patients of the program and participates in the bi-annual data quality check activity of PMDT. From August 1, 2021 to July 31, 2022, a total of 499 tests were conducted for patients of the PMDT.

4. Culture Laboratory of the PMDT program

As a part of the TB Culture Laboratory Network of the NTP, TDF renders its services to the following satellite treatment centers (STCs): North Daang Hari STC, Elias Aldana STC, TDF STC, West Rembo STC, BJMP MMDJ6 STC, and Masambong STC. Aside from STCs within the catchment area of TDF, the laboratory also provided services to STCs in Region III due to the renovation of their culture laboratory. For the fiscal year 2021-2022, a total of 3,288 samples were received and processed.

5. TMC207-C211

- A phase 2, open-label, multicenter, single-arm study to evaluate the pharmacokinetics, safety, tolerability and anti-mycobacterial activity of TMC207 in combination with a background regimen of multidrug resistant TB (MDR-TB) medications for the treatment of children and adolescents 0 months to <18 years of age who have confirmed or probably pulmonary MDR-TB.

- *Sponsor:*
  Janssen Research and Development

- *Laboratory Role:*
  Country Central Mycobacteriology Laboratory

- *Duration:* 10 years - 2016-2025

- *Test Conducted:* A total of 59 samples were received and processed for the FY 2021-2022

6. TRUNCATE TB

(Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis)

A randomized, open-label, multi-arm, multi-stage (MAMS), parallel group strategy trial.

- *Sponsor:*
  University College London is the trial legal sponsor and has delegated responsibility for the management of the trial to the National University Hospital (Singapore).

- *Laboratory Roles:*
  a. Central Mycobacteriology Laboratory
  b. Site Laboratory for TDF clinical site
  c. Central Biorepository.

- *Duration:* 2018-2022

- *Tests Conducted:* A total of 250 samples were received and processed for the FY 2021-2022

7. NC-008 (B-Pa-M-Z) / SimpliciTB

An open-label, partially randomized trial to evaluate the efficacy, safety and tolerability of a 4-month treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPaMZ) compared to a 6-month treatment of HRZE/HR (control) in adult participants with drug-sensitive, smear-positive pulmonary tuberculosis (DS-TB) and a 6-month treatment of BPaMZ in adult participants with drug-resistant, smear-positive pulmonary tuberculosis (DR-TB).

- *Sponsor:* Global TB Alliance
- *Laboratory Role:*
  Country Central Mycobacteriology Laboratory
- *Duration:* 2019 - 2022
  (The project offficially closed on July 27, 2022)
- *Test Conducted:* A total of 676 samples were received and processed for the entire duration of the project

8. Study 2021L001

A study to evaluate efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), inactivated in healthy adults aged 18 years and older.

- *Sponsor:*
  Shenzhen Kangtai Biological Products Co., LTD
- Laboratory Roles:
  Country Reference Laboratory for RT-PCR
- *Duration:* 2021-2022
- *Tests Conducted:*
  A total of 1,839 RT-PCR tests were conducted for the FY 2021-2022

9. STUDY JSVCT109

A Phase III, global multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of the recombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants aged 18 years and older who do not have a known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 or SARS-CoV-2 infection.

- *Sponsor:* WestVac Biopharma Co., LTD
- *Laboratory Role:*
  Country Reference Laboratory for RT-PCR
- *Duration:* 2021 - 2022
  (The project offficially closed on July 27, 2022)
- *Test Conducted:*
  A total of 1,350 RT-PCR tests were conducted for FY 2021-2022

10. PHOENIX MDR-TB

(Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients)

A Phase III, open-label, randomized clinical trial to compare the efficacy and safety of delamanid versus 26 weeks of isoniazid for preventing confirmed or probable active TB during 96 weeks of follow-up among high-risk household contacts of adults with multidrug-resistant TB.

- *Sponsor:*
  National Institute of Allergy and Infectious Diseases
- *Laboratory Role:*
  Contracted Mycobacteriology Laboratory
- *Duration:* 2019 – 2025

Tests Conducted:
A total of 140 samples from Index patients and 303 samples from Household patients were received and processed for FY 2021-2022

11. Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB (DRAMATIC)

A multicenter, randomized, partially blinded, four-arm, phase 2 study to examine the efficacy and safety of an all-oral regimen of bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine given for 16, 24, 32, or 40 weeks..

- *Sponsor:* Boston Universwity
- *Laboratory Role:* Contracted Mycobacteriology Laboratory
- *Duration:* 2022 – 2025

Tests Conducted:
Since the start of the project until July 31, 2022,
19 samples were received and processed

12. CoACH-RePORT Trial

TDF Laboratory was contracted by De La Salle Medical and Health Science Institute to provide TB Culture services for the CoACH-RePORT Trial.This project started on April 2022 and will end on February 2023. A total of 44 samples were received and processed since the start of the project until July 31, 2022.



13. THE EPIC PROJECT
MEETING TARGETS AND MAINTAINING EPIDEMIC CONTROL

The concept of a dual approach to addressing TB and HIV coinfections forms the basis for collaborative efforts between USAID, PEPFAR, the Department of Health, FHI360, and the Tropical Disease Foundation, Inc. (TDF). Currently, TDF manages an HIV project valued at Php 9.3 million, funded by USAID, which began implementation on March 15, 2022, and is scheduled to conclude on September 30, 2022. This project aims to assess the diagnostic effectiveness of pooling strategies on Dried Blood Spots (DBS) using the Cepheid GeneXpert HIV-1 qualitative assay.

The Meeting Targets and Maintaining Epidemic Control (EpiC) project is being executed in the National Capital Region (NCR), Region 3, and Region 4A. TDF, serving as the sub-grantee for this project, collaborates with FHI360, the Principal Grantee, in partnership with the DOH-Metro Manila Center for Health Development and the National Reference Laboratory – STI/AIDS Central Cooperative Laboratory (NRL-SACCL). The focus of this partnership is to address gaps in patient catchment and ensure linkage to treatment, care, and support.

As a sub-grantee of the EpiC project, TDF has the potential to make significant strides in early diagnosis during the Acute HIV infection stage. This potential is realized through its utilization of "Pooling strategies on Dried Blood Spot collection using the Cepheid GeneXpert HIV-1 qualitative assay" study. Pioneering research during the Acute HIV Stage not only contributes to the body of knowledge surrounding these diseases but also advances the long-term goal of enhancing medical care approaches, ultimately improving the quality of life for People Living with HIV (PHLIV).

TDF's HIV program boasts a well-established Logical Framework for its developed programs, coupled with an effective Monitoring and Evaluation Workplan. These tools ensure that all donor-funded projects and programs align with the donors' objectives and contribute to the Foundation's key performance indicators, goals, and vision.

To give a glimpse of our collaborative achievements:

On RESEARCH

- Development of Protocol
- Training of Dried Blood Spot Collection

On LABORATORY

- Establishment of HIV Laboratory
- Training of HIV & rHIVDa proficient Med Techs

On CLINIC

- Newly renovated HIV clinic
- Primary Care trained Clinic Staff
- Onboarding of Clinical Case Manager
- Organizing TDF - HACT (HIV-AIDS Core Team)

TDFI Epic Team and Epic – FHI 360 collaboration on conducting the first scientific summit focusing on HIV, titled IGNIS: Implementing Goals, Novel Interventions Summit. held at Ascott Hotel Makati – September 20 – 23, 2022



USAID and PEPFAR delegates conducted a Facility Visit to Tropical Disease Foundation, Inc. – October 7, 2022





June 7, 2022 - DOH -MMCHD, (Dr. Deidra Parrish and Mr. Mikael Navarro of USAID, Ms. Clarence Faye Salvador and Mr. Jeremiah Serrano of FHI360 with Dr Julius Lecciones and TDFI EPIC Project Team) USAID conducted a site visit on TDFI for assessment on HIV Testing Facility Set-up and rHIVDA laboratory accreditation.





June 21-23, 2022 - TDFI EpiC Team conducted the Pilot training on Dried Blood Spot Collection held at Jade Hotel and Suites Makati attended by top CBS Motivators from HASH (NCR, LAGUNA, CAVITE) and LAKAN (REGION 3)

TDFI Conducted a Technical Working Group Workshop at Splendido Hotel Tagaytay - August 24 – 26, 2022. Attended by fhi360, DoH Region 3, HASH, LAKAN, and Sail.

HIV Counseling to Testing Training facilitated by CAMP Pag-ayo Inc., held at Jade Hotel and Suites

TDFI Conducted a Monitoring and Evaluation Workshop from July 26-29, 2022 at Tiara Oriental Hotel Makati, Photo taken on the last day of the training upon awarding of certificates to the participants. Joined in the photo are the Panelist from FHI 360 Philippines (Ms. Teresita Bagasao, Dr. Stanley Carrasco, Ms. Clarence Faye Salvador and Ms. Bettina Kaye Castaneda), training Facilitators from CAMP (Dr. Jonathan Fontilla, Mr. Joemer Salamat and Mr. Ian Felix Alquiros) and Mr. Rogeselle Monton, TDFI EpiC Project Manager.

HIV Primary Care Training facilitated by SHIP INC., held at Privato Hotel Makati from May 11-13, 2022. Attended by TDFI EpiC Project Staff and other HIV organizations.


Partnerships

1. Community Engagement Project (Global TB Alliance)

With the onset of community quarantine in response to the Covid-19 pandemic, the project shifted its activities to online webinars highlighting the challenges and experiences brought about by TB through the perspectives of public partners and patients. 6 webinar sessions have been produced together with TB People PH.

The project started in Oct 2019 and ended Dec 2021.

2. TDF-Radisen X-ray Facility

Radisen, a developer of artificial intelligence (AI) technology for digital radiography, provided equipment for TDF to establish an x-ray facility on-site. The facility uses AI technology in parallel with standard radiographic reading to help Radisen further develop their AI system.

Launch Date: 27 SEP 2021

Partnership with TB People Started JAN 2022 to cover chest x-ray procedure for contacts of registered patients, with priority for pediatric contacts.

Clients accommodated for Fiscal Year: 90 (22 through the support of TBPeoplePH)

3. Wellcome - CCP Project

The Foreign, Commonwealth & Development Office / Wellcome Epidemic Preparedness awarded grant to the University of Oxford to roll-out **International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Clinical Characterisation Protocol (CCP)** in Low- and Middle-Income Countries (LMICs). In Southeast Asia, TDF was chosen to be the Regional Research Coordinator to roll-out the project.

The purpose of the study is to [1] harmonize data collection for independent (local) and pooled (global) analysis and to [2] clinically characterize COVID-19 in the acute phase and assess the risk of long-term health sequelae in persons who recovered from the disease, to identify risk factors, immunological responses, and biomarkers for severe disease.

Protocol Title: "International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Clinical Characterisation Protocol (CCP)"

Protocol Name: ISARIC CCP

Sponsor: Foreign, Commonwealth & Development Office/ Wellcome Epidemic Preparedness

Start Date: ..... June 1, 2021
End Date (Initial Grant):.....November 30, 2022

Accomplishments:
Pilot Site: ..... Makati Medical Center
IRB Protocol No.:.....MMCIRB 2021-184
Number of Covid-19 cases
encoded in Philippines CCP Database:..... 445

4. Covid-19 Molecular Laboratory partnership with BRHI

Tropical Disease Foundation, Inc.'s COVID-19 Molecular Laboratory conducted 72,771 RT-PCR tests for its partner Bloomberry Resorts and Hotels, Inc.for the FY 2021-2022.

5. Leveraging Innovations for Faster Treatment of Tuberculosis (LIFT-TB) Project (BPaL OR)

Paving the way towards a novel, more effective and safer treatment of drug-resistant TB

PROFILE: Launched in December 2020, the LIFT-TB Philippines is a two-year project supported by the TB Alliance through the International TB Research Center (ITRC, South Korea) and KNCV, Netherlands, that supports the conduct of an operational research (OR) on the WHO-recommended novel short-all oral BPaL (Bedaquiline, Pretomanid and Linezolid) regimen in the Philippines in collaboration with the Department of Health, Jose B. Lingad Memorial General Hospital , Lung Center of the Philippines, National TB Reference Laboratory, Philippine Business for Social Progress and Tropical Disease Foundation, Inc. (TDF). TDF serves as the local coordinating arm of the Project

The OR is being implemented in 12 PMDT facilities across 10 regions. It has surpassed its target of 100 enrollees in November 2022, one month ahead of its target schedule. To date, the Project is gearing up for a two-year extension in support of the programmatic nationwide scale-up of the BPaL regimen.

OUR OBJECTIVE:
To assess the effectiveness and safety of the new short oral BPaL regiment for the treatment of multi-drug resistant TB (MDR-TB) and extremely drug resistant TB (XDR-TB).

OUR TARGET:
100 MDR/XDR TB patients enrolled (started in May 2021)
***Target reached in November**



ACCOMPLISHMENT HIGHLIGHTS

August 2021 – July 2022

Enrollment and Eligibility



Treatment Outcome

First BPaL Graduate

As of July 2022, there were 66 enrolled patients, of these 20 had treatment outcomes with culture results (May – Dec 2021). Among these, **all were successfully treated** with 9 (45%) declared cured based on culture conversion from positive at baseline to negative at the end of treatment and 11 (55%) treatment completed.

41

Fluoroquinolone resistant (Fq-R) diagnosed and treated



Laboratory strengthening: Rapid expansion of Xpert /MTB XDR utilization

ACCOMPLISHMENT HIGHLIGHTS

August 2021 – July 2022



TECHNICAL SUPPORT

- Project implementation review (PIR) conducted and participated by **169** stakeholders in Jan 2022
- Development of job aids, Clinical Guidelines and revision of Implementation Plan



CAPACITY BUILDING

22 participants trained on REDCap (data management software) in Jun 2022

Trainings

EXTRAMURAL

MAKATI MEDICAL CENTER FELLOWSHIP ROTATION PROGRAM

Training program with MMC Infectious Diseases and Pulmonology Departments for fellows to be familiarized with clinical and laboratory TB management. The program started September 2014, and TDF has accommodated 4 fellows for the current year.

INTRAMURAL

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Angelito M. Catindig Ma. Lourdes O. Cabanatan Maria Teresa A. Caridad	Portfolio Management and Customer Onboarding	August 19, 2021
Anthony A. Geronimo	Joint GLI-GDI Workshop: Access to Diagnostics, Treatment and Care to End TB	October 14, 2021

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Mark Joseph I. Palec Ma. Joanna Eunice P. Calaoagan Trizia Maye P. Suriaga Liezl A. Carlos Dr. Karina Michaela F. Tacujan Tristan Nicole B. Evangelista Harley Ronniekson A. Kihom Angela Marie R. Mendoza Elizabeth Julian C. Batoy	Training for Pooling of Samples for RT-PCR Testing for the detection of SARS-CoV-2	November 17, 19, December 1, 2021
Phoebe Hannah DC Bauzon	Online Training for the performance of TB Culture using Modified Kudoh Method	December 6-10, 2021
John Phillip C. Ubalde	Basic Occupational Safety and Health for Safety Officer II	February 21-25, 2022
Christine Larryse Evangelista Ricardo T. Taylo Jr	Basic Occupational Safety And Health For Safety Officer I	March 16-17, 2022
Evelyn S. Joson	Microsoft Azure Fundamentals	March 20, 2022

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Rupert Rey J. Flores Elma D. Villamina, RM Abigail S. Daluz, RPh Ronald E. Darjuan Harley Ronniekson A. Kihom, RMT John Philip C. Ubalde, RN Christian D. Salido Emmanuel D. Reyes Reynaldo D. Dioric	Basic Occupational Safety and Health for Safety Officer II HIV Counseling to Testing Training (Batch 1)	March 21-25, 2022 April 26-28, 2022
Rogeselle Monton Elma D. Villamina John Phillip Cudal Ubalde Harley Ronniekson A. Kihom Ma. Joanna Eunice P. Calaoagan Rholine Gem Martin S Veto Emmanuel Reyes	HIV Primary Care Training (Batch 1)	May 10-14, 2022

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Anthony A. Geronimo Maita D. Benavente	8th Asia Pacific Region Conference of International Union Against TB and Lung Disease	May 27-28, 2022
Anthony A. Geronimo Rupert Rey J. Flores	2022 rHIVda Training Course	June 13-16, 2022
Marita I. Nucum	Worker's Institute on Labor Laws Class 183	July 25-30, 2022
Harley Ronniekson Kihom Emmanuel Reyes Ma. Joanna Eunice Calaoagan Camille Ocampo Catherine Anne Dente Glenn I. Balane Evelyn S. Joson	Workshop on Monitoring and Evaluation	July 26-29, 2022

Financial Summary

REYES TACANDONG & CO.

INDEPENDENT AUDITORS' REPORT

The Board of Trustees
Tropical Disease Foundation, Inc.
Philippine Institute of Tuberculosis Building
Amorsolo corner Urban Avenue
Barangay Pio Del Pilar, Makati City

Opinion

We have audited the accompanying financial statements of Tropical Disease Foundation (the Foundation), a non-stock, non-profit organization, which comprise the statements of liabilities and fund balances as at July 31, 2022 and 2021, and the statements of revenues and exp statements of changes in fund balances and statements of cash flows for the years then including a summary of significant accounting policies.

In our opinion, the financial statements present fairly, in all material respects, the financial posi the Foundation as at July 31, 2022 and 2021, and its financial performance and its cash flows years then ended in accordance with Philippine Financial Reporting Standard for Small and M sized Entities (PFRS for SME).

Basis for Opinion

We conducted our audits in accordance with Philippine Standards on Auditing (PSA). Our respons under those standards are further described in the *Auditors' Responsibilities for the Audit Financial Statements* section of our report. We are independent of the Foundation in accordan the Code of Ethics for Professional Accountants in the Philippines (Code of Ethics) together w ethical requirements that are relevant to the audit of the financial statements in the Philippines, have fulfilled our other ethical responsibilities in accordance with these requirements and the C Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to pr basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statem accordance with PFRS for SME, and for such internal control as management determines is nece enable the preparation of financial statements that are free from material misstatement, wheth to fraud or error.

In preparing the financial statements, management is responsible for assessing the Foundation' to continue as a going concern, disclosing, as applicable, matters related to going concern and u going concern basis of accounting unless management either intends to liquidate the Foundatio cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with PSA will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, these could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with PSA, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

REYES TACANDONG & CO.

DAPHNE A. JAMOTILLO
Partner
CPA Certificate No. 100839
Tax Identification No. 206-551-885-000
BOA Accreditation No. 4782, Valid until April 13, 2024
SEC Accreditation No. 100039-SEC Group A
Issued August 3, 2021
Valid for Financial Periods 2021 to 2025
BIR Accreditation No. 08-005144-018-2021
Valid until July 1, 2024
PTR No. 8851721
Issued January 3, 2022, Makati City

November 10, 2022
Makati City, Metro Manila

TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF ASSETS, LIABILITIES AND FUND BALANCES

	Note	July 31 2022	2021
ASSETS			
Current Assets			
Cash and cash equivalents	4	₱64,581,113	₱31,511,886
Receivables	5	13,086,539	12,141,368
Investments in trust fund	6	72,979,865	68,966,888
Other current assets		428,536	367,375
Total Current Assets		151,076,053	112,987,517
Noncurrent Assets			
Investment property	7	3,085,742	4,086,807
Property and equipment	8	63,211,974	63,594,343
Other noncurrent assets	9	505,174	729,616
Total Noncurrent Assets		66,802,890	68,410,766
		₱217,878,943	₱181,398,283
LIABILITIES AND FUND BALANCES			
Current Liabilities			
Accrued expenses and other payables	10	₱12,779,530	₱7,315,397
Income tax payable		–	309,295
Total Current Liabilities		12,779,530	7,624,692
Noncurrent Liabilities			
Net retirement benefit liability	17	4,334,004	8,225,082
Deferred tax liability	18	52,147	–
Total Noncurrent Liabilities		4,386,151	8,225,082
Total Liabilities		17,165,681	15,849,774
Fund Balances			
General fund		134,380,572	97,822,521
Capital fund		33,924,716	35,308,150
Restricted fund	12	32,373,000	32,373,000
Other comprehensive income		34,974	44,838
Total Fund Balances		200,713,262	165,548,509
		₱217,878,943	₱181,398,283

See accompanying Notes to Financial Statements.

TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF REVENUES AND EXPENSES

	Note	Years Ended July 31 2022	2021
REVENUES			
Sources of funds	13	₱144,180,489	₱79,938,946
PROGRAM EXPENSES	14	(92,290,629)	(68,502,306)
GENERAL AND ADMINISTRATIVE EXPENSES	15	(20,900,398)	(8,307,295)
OTHER INCOME	16	6,900,568	8,390,825
EXCESS OF REVENUES OVER EXPENSES BEFORE INCOME TAX		37,890,030	11,520,170
PROVISION FOR INCOME TAX	18		
Current		(2,663,266)	(557,532)
Deferred		(52,147)	–
		(2,715,413)	(557,532)
EXCESS OF REVENUES OVER EXPENSES		35,174,617	10,962,638
OTHER COMPREHENSIVE LOSS			
Item to be reclassified to profit or loss when realized			
Unrealized loss on fair value changes of investments	9	(9,864)	(864)
TOTAL COMPREHENSIVE INCOME		₱35,164,753	₱10,961,774

See accompanying Notes to Financial Statements.

NOV 25 2022

See accompanying Notes to Financial Statements.

TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CHANGES IN FUND BALANCES

	Note	Years Ended July 31 2022	2021
GENERAL FUND BALANCE			
Balance at beginning of year		₱97,822,521	₱86,278,676
Excess of revenues over expenses		35,174,617	10,962,638
Transfer from capital fund	8	8,608,773	8,407,591
Transfer to capital fund	8	(7,225,339)	(7,826,384)
Balance at the end of year		134,380,572	97,822,521
CAPITAL FUND BALANCE			
Balance at beginning of year		35,308,150	35,889,357
Transfer to general fund	8	(8,608,773)	(8,407,591)
Additions to property and equipment	8	7,225,339	7,826,384
Balance at the end of year		33,924,716	35,308,150
RESTRICTED FUND BALANCE	12	32,373,000	32,373,000
OTHER COMPREHENSIVE INCOME			
Reserve for fair value changes of investments			
Balance at beginning of year		44,838	45,702
Unrealized loss on fair value changes	9	(9,864)	(864)
Balance at the end of year		34,974	44,838
		₱200,713,262	₱165,548,509

See accompanying Notes to Financial Statements.

TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CASH FLOWS

	Notes	Years Ended July 31 2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES			
Excess of revenues over expenses before income tax		₱37,890,030	₱11,520,170
Adjustments for:			
Depreciation and amortization	8	8,608,773	8,407,591
Investment income	6	(3,776,585)	(5,415,919)
Donated laboratory equipment	8	(2,983,470)	(2,757,694)
Retirement benefit expense (income)	17	1,659,518	(5,099,812)
Loss on write-off of receivables	5	844,572	540,959
Interest income	4	(29,585)	(24,155)
Excess of revenues over expenses before working capital changes		42,213,253	7,171,140
Decrease (increase) in:			
Receivables		(1,789,742)	2,325,608
Other current assets		(61,161)	231,058
Other noncurrent assets		214,578	(277,500)
Increase (decrease) in accrued expenses and other payables		5,464,132	(2,046,025)
Net cash generated from operations		46,041,060	7,404,281
Benefits paid	17	(5,550,596)	(316,773)
Income tax paid		(2,972,561)	(248,237)
Interest received		29,585	24,155
Net cash provided by operating activities		37,547,488	6,863,426
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from withdrawals of investments in trust funds		31,548,392	62,849,206
Additions to:			
Investments in trust funds		(35,561,369)	(57,390,651)
Property and equipment	8	(4,241,869)	(5,068,690)
Investment income received		3,776,585	5,415,919
Net cash provided by (used in) investing activities		(4,478,261)	5,805,784
NET INCREASE IN CASH AND CASH EQUIVALENTS		33,069,227	12,669,210
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		31,511,886	18,842,676
CASH AND CASH EQUIVALENTS AT END OF YEAR	4	₱64,581,113	₱31,511,886
NONCASH FINANCIAL INFORMATION			
Donated laboratory equipment	8	₱2,983,470	₱2,757,694

See accompanying Notes to Financial Statements.

BOARD OF TRUSTEES

CHAIRMAN OF THE BOARD

Dr. Ruben L. Encarnacion

MEMBERS

Dr. Claver P. Ramos

Dr. Roberta C. Romero

Dr. Camilo C. Roa Jr.

Dr. Socorro P. Lupisan

Dr. Raymundo W. Lo

Arch. Pablo R. Antonio Jr.

Mrs. Mercedes A. Solon

Atty. Edwin R. Abella

EXECUTIVE OFFICERS

PRESIDENT AND CEO
Julius A. Lecciones, MD, PhD, DPA

VP FOR PROGRAM SUPPORT
Leilani C. Naval

MANAGEMENT OFFICERS

LABORATORY MANAGER
Anthony A. Geronimo

CLINIC PHYSICIAN
Dr. Rholine Gem Martin S. Veto

FINANCE MANAGER
Rhandy R. Rowan

HR MANAGER
Marita I. Nucum

IT MANAGER
Evelyn S. Joson

PROGRAM MANAGER, EPIC
Rogeselle B. Monton

CONTACT US

Website: www.tdf.org.ph
Email: inquiries@tdf.org.ph
Telephone: +632 8894 0741/43